After tackling toxicity and a trial halt, Elena Koundourakis and her team at Takeda are on the cusp of a first-in-class drug for people living with narcolepsy.
Activating specific neurons using light helped scientists establish a causal link between improved sleep and diminished signs of Alzheimer’s disease in mice.